GlassScriptPhysician profile
Naureen S Ahmeduddin
NPI 1427284553
$2,385.00
in general payments reported to CMS, 2019-2025
20 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $18.09 · 2021: $75.93 · 2022: $146 · 2023: $529 · 2024: $739 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $676.62 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $512.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $246.88 | 2022-2025 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Lilly USA, LLC | $135.40 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $129.40 | 2021-2025 | |
| Exact Sciences Corporation | $126.06 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $119.98 | 2022-2025 | Repatha, Otezla, Otezla |
| Boston Scientific Corporation | $94.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.68 | 2024-2025 | |
| Shield Therapeutics INC | $48.82 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $46.71 | 2020-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $45.61 | 2019-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Dynavax Technologies Corporation | $26.64 | 2023 | Heplisav-B |
| Inspire Medical Systems, INC. | $21.07 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $20.42 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.32 | 2019 | |
| Currax Pharmaceuticals LLC | $16.51 | 2025 | Contrave |
| Antares Pharma, INC. | $15.73 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naureen Ahmeduddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.